The survey of more than 400 specialty pharmacists also found that nearly two-thirds of specialty pharmacists report spending more than 15 minutes on the phone to fill one prescription, and 79% of specialty pharmacists seek additional information from clinicians at least three times in an average day.
Specialty medications that treat serious and chronic conditions like cancer, multiple sclerosis and rheumatoid arthritis have complex documentation requirements.
When combined with a manual prior authorisation process, the result is an overwhelming amount of administrative work that gets in the way of pharmacists spending enough time with patients.
In fact, 40% of specialty pharmacists say the process is so burdensome that they feel more like an admin than a pharmacist.
Given the complex nature of specialty medications, this often leads to a seemingly endless cycle of phone calls and faxes with prescribers to obtain necessary information.
In fact, 39% of specialty pharmacists say they seek additional information from their clinician counterparts five times or more each day.
The administrative burden of specialty medications is resulting in increased burnout among care providers, including pharmacists.
The Surescripts survey found that 71% of specialty pharmacists are somewhat, very or extremely stressed at work, and 63% identified prior authorization as a source of stress.
According to a study in the American Journal of Health-System Pharmacy, more than half of health-system pharmacists have a high degree of burnout.
Most specialty pharmacists agree that an automated system would help.
The survey found that 86% of specialty pharmacists say getting more complete information from clinicians would improve patient care, and 56% think streamlined communication, specifically, secure messaging within their workflow, would improve the fulfillment process.
Surescripts partnered with Survata to administer the 33-question online survey to 414 active specialty pharmacists. Their responses were collected February 19–25, 2020.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial